Optimizing gene payload begins with plasmid design, and NanoplasmidsTM provide several advantages over traditional plasmids. That’s the focus of our latest webinar, done in collaboration with Phacilitate, as a panel of Aldevron experts discuss the unique opportunities associated with using nanoplasmids.
October 6, 2022
11 a.m. – Noon, Eastern Time (10 -11 a.m., CT)
With benefits across applications including transposons, HDR/CRISPR, viral vectors, and mRNA; nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic marker that can cause regulatory concerns.
What to expect
The panel will address the unique opportunities associated with using nanoplasmids over traditional plasmids (dependent on application), including:
- AAV application: safety benefits
- Lentiviral application: significant increase in viral titres and additional safety benefits
- Cell therapy: reduced cell death which leads to improved performance and longevity.
Following the panel discussion, a live Q&A session will follow, offering you a chance to pose questions to our experts and learn even more about Nanoplasmids.